AlphAIAlphAI — Financial news for AI agents
MarketBeatAPR 283 min read$COGT

Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Drop in Short Interest

Cogent Biosciences (NASDAQ:COGT) experienced a significant 30.9% drop in short interest in April, totaling 12,038,491 shares. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $43.45. Trading near $36.56, Cogent Biosciences has a market capitalization of $6.24 billion and recently reported a quarterly loss of ($0.55) EPS.

Original reporting
MarketBeat · MarketBeat
Published Apr 28, 2026, 6:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 28, 2026, 7:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Drop in Short Interest — source image
Source · MarketBeat
Decision brief

The 30-second read

$COGTNeutralMed
01

Why it matters

The reduction in short interest might lead to increased buying pressure, potentially supporting a price rebound.

02

Market read

While the short interest drop is significant, its impact is moderate given the company's recent earnings and current valuation.

03

What to watch

Broader market downturns or sector-specific risks could negate positive sentiment; recent earnings report indicates ongoing challenges.

Relevance 6/10Timing: short-term (next 1-4 weeks)

Background

Cogent Biosciences experienced a notable decrease in short interest, which can signal changing investor sentiment or expectations.

Company-level read

Ticker impact

$COGTNeutralMedium confidence
Context

The significant drop in short interest indicates a potential shift in market sentiment for Cogent Biosciences.

Expected impact

Moderate upward price correction expected over the next 4-6 weeks, contingent on company fundamentals and broader market conditions.

Evidence & confidence

The substantial reduction in short interest may signal waning bearish sentiment, but the company's recent quarterly loss and current trading price suggest caution. Technical indicators and industry comparisons are not provided, limiting precise predictions.

Market effects

Sector

Potential positive sentiment shift in biotech and life sciences sectors due to reduced short interest in a key player.

Regional

Limited regional impact; primarily affects US-based biotech sector.

Global

Minimal; company-specific news with limited global implications.

Counterpoint

What could challenge this read

The decline in short interest may be a temporary correction; underlying fundamentals remain weak due to quarterly losses.

Key entities

  • Company
    Cogent Biosciences, Inc.

    A biotechnology company focused on developing targeted therapies.

Read at source← All news

Related articles

SEP 15
$COGTHighAI 8/10

Cogent's Bezuclastinib NDA Accepted For Advanced Systemic Mastocytosis; PDUFA Set For June 2027

Cogent Biosciences (COGT) announced FDA acceptance of its NDA for Bezuclastinib to treat Advanced Systemic Mastocytosis, with a PDUFA target date of June 2027. The NDA is supported by APEX trial data showing a 65% overall response rate and 79% 12-month progression-free survival. The FDA has not identified any review issues. COGT is also advancing NDAs for other indications. The stock is currently trading at $33.49, up 0.24%.

rttnews.com2 min
AUG 10
$COGTMed

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Cogent Biosciences, Inc. (COGT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Applicatio

SEC EDGAR 8-K6 min
OCT 24
$AZNHigh

A lung cancer trial found 21.1 months’ median survival with two drugs, versus 12.7 with one.

AstraZeneca's trial showed IMFINZI plus tarlatamab-dlle improved median survival to 21.1 months vs. 12.7 months with IMFINZI alone in extensive-stage small cell lung cancer. The combination reduced death risk by 58% and progression risk by 66%. Results were consistent across subgroups, including brain metastases. AstraZeneca aims to redefine treatment standards. Data presented at ESMO Congress 2026.

stocktitan.net3 min
OCT 24
$AMGNHigh

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Amgen (AMGN) announced that IMDELLTRA® combined with AstraZeneca's IMFINZI® reduced the risk of death by 58% in extensive stage small cell lung cancer (ES-SCLC) patients. Median overall survival increased to 21.1 months from 12.7 months with IMFINZI alone. The Phase 3 DeLLphi-305 study results were presented at ESMO Congress 2026 and published in The New England Journal of Medicine.

prnewswire.com2 min